Oral Bioavailability Enhancement of Β-Lapachone, a Poorly Soluble Fast Crystallizer, by Cocrystal, Amorphous Solid Dispersion, and Crystalline Solid Dispersion.
Chengyu Liu,Zhengsheng Liu,Yuejie Chen,Zhen Chen,Huijun Chen,Yipshu Pui,Feng Qian
DOI: https://doi.org/10.1016/j.ejpb.2017.12.016
IF: 5.589
2018-01-01
European Journal of Pharmaceutics and Biopharmaceutics
Abstract:The aim of this paper was to compare the in vitro dissolution and in vivo bioavailability of three solubility enhancement technologies for beta-lapachone (LPC), a poorly water soluble compound with extremely high crystallization propensity. LPC cocrystal was prepared by co-grinding LPC with resorcinol. LPC crystalline and amorphous solid dispersions (CSD and ASD) were obtained by spray drying with Poloxamer 188 and HPMC-AS, respectively. The cocrystal structure was solved by single crystal x-ray diffraction. All formulations were characterized by WAXRD, DSC, POM and SEM. USP II and intrinsic dissolution studies were used to compare the in vitro dissolution of these formulations, and a crossover dog pharmacokinetic study was used to compare their in vivo bioavailability. An 1:1 LPC-resorcinol cocrystal with higher solubility and faster dissolution rate was obtained, yet it converted to LPC crystal rapidly in solution. LPC/HPMC-AS ASD was confirmed to be amorphous and uniform, while the crystal and crystallite sizes of LPC in CSD were found to be similar to 1-3 mu m and around 40 nm, respectively. These formulations performed similarly during USP II dissolution, while demonstrated dramatically different oral bioavailability of similar to 32%, similar to 5%, and similar to 1% in dogs, for CSD, co-crystal, and ASD, respectively. CSD showed the fastest intrinsic dissolution rate among the three. The three formulations showed poor IVIVC which could be due to rapid and unpredictable crystallization kinetics. Considering all the reasons, we conclude that for molecules with extremely high crystallization tendency that cannot be inhibited by any pharmaceutical excipients, size-reduction technologies such as CSD could be advantageous for oral bioavailability enhancement in vivo than technologies only generating transient but not sustained supersaturation.